首页> 外国专利> A COMBINATION OF RILPIVIRINE OR AN EQUIVALENT THERAPEUTIC FORM THAT IS DIRECTED THEREFROM PROTECTED BY THE BASIC PATENT, SUCH AS A PHARMACEUTICALLY ACCEPTABLE SALT OF RILPIVIRINE, INCLUDING THE RILPIVIRINE HYDROCHLORIDE SALT, AND TENOFOVIR, IN PARTICULAR TENOFOVIR DISOPROXIL FUMARATE

A COMBINATION OF RILPIVIRINE OR AN EQUIVALENT THERAPEUTIC FORM THAT IS DIRECTED THEREFROM PROTECTED BY THE BASIC PATENT, SUCH AS A PHARMACEUTICALLY ACCEPTABLE SALT OF RILPIVIRINE, INCLUDING THE RILPIVIRINE HYDROCHLORIDE SALT, AND TENOFOVIR, IN PARTICULAR TENOFOVIR DISOPROXIL FUMARATE

机译:由基本专利保护的利福昔林或其等效治疗形式的组合,例如药学上可接受的利福韦林盐,包括利福韦林盐酸盐酸盐和替诺韦夫布洛韦

摘要

The present invention concerns combinations of a pyrimidine containing NNRTI with nucleoside reverse transcriptase inhibitors and/or nucleotide reverse transcriptase inhibitors useful for the treatment of HIV infected patients or for the prevention of HIV transmission or infection.
机译:本发明涉及含有嘧啶的NNRTI与核苷逆转录酶抑制剂和/或核苷酸逆转录酶抑制剂的组合,可用于治疗HIV感染的患者或预防HIV的传播或感染。

著录项

  • 公开/公告号LU92854I2

    专利类型

  • 公开/公告日2015-12-21

    原文格式PDF

  • 申请/专利权人 JANSSEN SCIENCES IRELAND UC;

    申请/专利号LU20150092854C

  • 发明设计人

    申请日2015-10-21

  • 分类号A61K31/505;A61K31/513;A61K31/52;A61P31/18;

  • 国家 LU

  • 入库时间 2022-08-21 14:24:25

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号